Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
NCT05823246 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2023-05-26
Summary
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
Conditions
Interventions
- DRUG
-
QLF31907
Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
Sponsors & Collaborators
-
Qilu Pharmaceutical Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-24
- Primary Completion
- 2023-10-31
- Completion
- 2024-07-31
Countries
- China
Study Locations
More Related Trials
-
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
NCT05051865 ·Status: UNKNOWN ·Phase: PHASE2
-
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
NCT05928962 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
NCT02619058 ·Status: UNKNOWN ·Phase: PHASE1
-
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804 ·Status: COMPLETED ·Phase: PHASE2
-
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
NCT04357509 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
NCT04653038 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED
-
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
NCT05732805 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
NCT02821000 ·Status: COMPLETED ·Phase: PHASE1
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
NCT05135715 ·Status: RECRUITING ·Phase: PHASE2
-
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
NCT00658437 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
NCT01245556 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
NCT01137006 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
NCT07040436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
NCT01960829 ·Status: UNKNOWN ·Phase: PHASE2
-
Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
NCT03673332 ·Status: TERMINATED ·Phase: PHASE4
-
HL-085 in NRAS-mutated Advanced Melanoma
NCT05217303 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II, 2nd Line Melanoma - RAND Monotherapy
NCT00612664 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
NCT03430297 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
NCT03454919 ·Status: UNKNOWN ·Phase: PHASE2
-
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
NCT04620603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1